To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.
When autocomplete results are available use up and down arrows to review and enter to select.
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Study Purpose
Despite the implementation of modern public health interventions, 1 in 5 adults in the United
States are either current or former smokers and remain at risk for the development of chronic
lung diseases. It is unknown how or why any one individual smoker can develop a wide range of
lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The
purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar
samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles
that correspond to divergent pathways in the expression of such proteins as the transforming
growth factor-beta1 (TGF- <=1). The information generated from this study will provide
insight into the pathogenesis of smoking-related lung injury and potentially allow for the
development of early therapeutic interventions.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms
Yes
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.
An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.
Searching Both is inclusive of interventional and observational studies.
Observational
Eligible Ages
40 Years - 80 Years
Gender
All
More Inclusion & Exclusion Criteria
- INCLUSION CRITERIA
For subjects with lung diseases:
- Men and women age 40-80 years
- Smokers with greater than or equal to 10 pack-year history of ever-smoking
EXCLUSION CRITERIA
For subjects with lung diseases:
Subjects will be excluded from the study if they meet one or more of the following
criteria:
- Subjects who are under the age of 40 or over 80 years old
- Women who are pregnant or lactating
- Have known allergies to lidocaine or medications used for moderate sedation
- Active coronary artery disease
- Cerebral-vascular accident within the past 12 months
- Active anticoagulation
- Active infections
- Cancer, or a history of cancer within the previous 5 years of screening (other than
adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or
carcinoma in situ of the uterine cervix with no evidence of recurrence).
- Poorly controlled chronic diseases
- Unable to provide consent
- Impaired renal function (including dialysis)
- Contraindications to MRI scan including:
- electrical implants such as cardiac pacemakers or perfusion pumps
- ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,
artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos
near the eye, or steel implants
- ferromagnetic objects such as jewelry or metal clips in clothing
- pre-existing medical conditions, including a likelihood of developing seizures or
anxiety disorders such as claustrophobia, panic attacks or any psychiatric
disorder
INCLUSION CRITERIA
For Non-Smoking Controls
- Men and women age 40-80 years
- No prior history of smoking (this is a non-smoking cohort)
EXCLUSION CRITERIA
For Non-Smoking Controls
- Subjects who are under the age of 40 or over 80 years old
- Women who are pregnant or lactating
- Have known allergies to lidocaine or medications used for moderate sedation
- Active coronary artery disease
- Cerebral-vascular accident within the past 12 months
- Active anticoagulation
- Active infections
- Cancer, or a history of cancer within the previous 5 years of screening (other than
adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or
carcinoma in situ of the uterine cervix with no evidence of recurrence).
- Poorly controlled chronic diseases
- Unable to provide consent
- Impaired renal function (including dialysis)
- Contraindications to MRI scan including:
- electrical implants such as cardiac pacemakers or perfusion pumps
- ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,
artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos
near the eye, or steel implants
- ferromagnetic objects such as jewelry or metal clips in clothing
- pre-existing medical conditions, including a likelihood of developing seizures or
anxiety disorders such as claustrophobia, panic attacks or any psychiatric
disorder
INCLUSION CRITERIA
For Smoking Controls
- Men and women age 40-80 years
- Subjects who have a prior smoking history
EXCLUSION CRITERIA
For Smoking Controls
- Subjects who are under the age of 40 or over 80 years old
- Women who are pregnant or lactating
- Have known allergies to lidocaine or medications used for moderate sedation
- Active coronary artery disease
- Cerebral-vascular accident within the past 12 months
- Active anticoagulation
- Active infections
- Cancer, or a history of cancer within the previous 5 years of screening (other than
adequately treated cutaneous basal cell, squamous cell carcinoma, excised melanoma, or
carcinoma in situ of the uterine cervix with no evidence of recurrence).
- Poorly controlled chronic diseases
- Unable to provide consent
- Impaired renal function (including dialysis)
- Contraindications to MRI scan including:
- electrical implants such as cardiac pacemakers or perfusion pumps
- ferromagnetic implants such as aneurysm clips, surgical clips, prostheses,
artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos
near the eye, or steel implants
- ferromagnetic objects such as jewelry or metal clips in clothing
- pre-existing medical conditions, including a likelihood of developing seizures or
anxiety disorders such as claustrophobia, panic attacks or any psychiatric
disorder
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.
Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.
Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.
Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.
National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study.
Joel Moss, M.D.
Principal Investigator Affiliation
National Heart, Lung, and Blood Institute (NHLBI)
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial.
NIH
Overall Status
Recruiting
Countries
United States
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied.
Despite the implementation of modern public health interventions, 1 in 5 adults in the United
States are either current or former smokers and remain at risk for the development of chronic
lung diseases. It is unknown how or why any one individual smoker can develop a wide range of
lung diseases including chronic obstructive lung disease and/or pulmonary fibrosis. The
purpose of this protocol is to collect clinical data, blood, urine, and bronchoalveolar
samples from smokers and non-smokers in an attempt to establish phenotypic clinical profiles
that correspond to divergent pathways in the expression of such proteins as the transforming
growth factor-beta1 (TGF- <=1). The information generated from this study will provide
insight into the pathogenesis of smoking-related lung injury and potentially allow for the
development of early therapeutic interventions.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Bethesda, Maryland
Status
Recruiting
Address
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892
Site Contact
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)